• Breakthroughs in MASH, with 89bio CEO

  • Jun 25 2024
  • Duración: 22 m
  • Podcast

Breakthroughs in MASH, with 89bio CEO Por arte de portada

Breakthroughs in MASH, with 89bio CEO

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • This week we’re focusing on an area of clinical research that has been of great interest for a number of years, that is NASH, also known as MASH.

    It’s a high area of unmet medical need, with over 20 million diagnosed cases across Europe and the USA, and while there are more than 80 therapies currently in the pipeline, only around 5% of these are in Phase III development.

    One company working in this area is San Francisco-based 89bio (Nasdaq: ETNB), which has a candidate now in Phase III, pegozafermin, and in this episode we are joined by the company’s chief executive, Rohan Palekar.

    We are also joined by Dr Arun Sanyal, who is Professor of Medicine at VCU Health and founder of the Liver Trust.
    Más Menos
activate_primeday_promo_in_buybox_DT
Política y Gobierno
Más Menos

Lo que los oyentes dicen sobre Breakthroughs in MASH, with 89bio CEO

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles